. . . . . "Kadmon Corporation, LLC."@en . . . . . . . . . . "37874974"^^ . . . . . . . "4"^^ . . . . . . . . . . "Kadmon Corporation (originally Kadmon Pharmaceuticals) is a biopharmaceutical company based in New York City. It also has operations in Warrendale, PA and Brighton, MA. The company was founded in 2009 by Samuel D. Waksal, founder and former CEO of ImClone Systems, now fully merged into Eli Lilly and Company. Waksal had served a federal prison sentence stemming from his fiduciary role as CEO in the 2001 ImClone stock trading case. When released in 2009 he was barred from serving as an officer for any publicly traded company but Kadmon was privately financed. In September 2014, amid plans to take the company to an IPO Harlan W. Waksal, brother of Samuel Waksal, became President and Chief Executive Officer while Samuel Waksal remained on with the title Chief of Innovation, Science and Strategy. In early 2016 Sam Waksal left Kadmon and in June the company filed paperwork for its IPO. On July 27, 2016 the company's stock began trading on the NYSE under the symbol KDMN but switched to NASDAQ in October 2020. On 8 September 2021, Sanofi announced it would acquire the company for $1.9 billion. The deal completed in November and its stock was deregistered as it became a subsidiary of Sanofi. As of 2019 Kadmon had ongoing clinical trials for KD025 in specific fibrotic and neurodegenerative diseases and tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD."@en . . "1122465492"^^ . . "Kadmon Pharmaceuticals logo.png"@en . . . "capecitabine, dofetilide, entecavir, ribavirin, temozolomide, tetrabenazine, tobramycin"@en . . "Kadmon Corporation"@en . . . . . . . "Harlan W. Waksal, MD"@en . "2009"^^ . . . . . . . . . . . . . . "4"^^ . . . . . . "Kadmon Corporation, LLC."@en . . . . . . . . . . . . . . "101"^^ . "Kadmon Corporation (originally Kadmon Pharmaceuticals) is a biopharmaceutical company based in New York City. It also has operations in Warrendale, PA and Brighton, MA. The company was founded in 2009 by Samuel D. Waksal, founder and former CEO of ImClone Systems, now fully merged into Eli Lilly and Company. Waksal had served a federal prison sentence stemming from his fiduciary role as CEO in the 2001 ImClone stock trading case. When released in 2009 he was barred from serving as an officer for any publicly traded company but Kadmon was privately financed."@en . . "New York, NY 10016"@en . . . "2009"^^ . . . "Anastasios G. Konidaris"@en . . . . . . . . . . . . . "19677"^^ . . . . . . "450"^^ . . . "101"^^ . . . . . .